On our screens:Stocks with no debtQuality compoundersQuality at a reasonable priceStocks that buy back more than they diluteand 1 more
The financials
Edwards Lifesciences by the numbers
Edwards Lifesciences (EW) reported revenue of $1.74B in Q2 2026 (quarter ended Jun 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $241M (14% of revenue). For the full year FY2025, revenue was $6.07B (+12% year on year) and net income $1.07B. Its largest product in Q2 2026 was Transcatheter Aortic Valve Replacement at $1.26B, 72% of the disclosed total, well ahead of Surgical at 16%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.74B | $1.53B | +14% |
| Gross profit | $1.35B | $1.19B | +14% |
| Operating income | $513M | $411M | +25% |
| Net income | $241M | $332M | −27% |
| Diluted EPS | $0.42 | $0.56 | −25% |
| Product | Revenue | Share |
|---|---|---|
| Transcatheter Aortic Valve Replacement | $1.26B | 72% |
| Surgical | $284M | 16% |
| Transcatheter Mitral And Tricuspid Therapies | $199M | 11% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.74B (+5.6%)
Transcatheter Mitral And Tricuspid Therapies grew +48% year on yearSurgical +6.5% year on year
Segment Latestquarter on quarteryear on year
- Transcatheter Aortic Valve Replacement$1.26B$1.26BQoQ +5.1%year on year +11%+5.1%+11%
- Surgical$284.1M$284.1MQoQ +2.9%year on year +6.5%+2.9%+6.5%
- Transcatheter Mitral And Tricuspid Therapies$198.6M$198.6MQoQ +13%year on year +48%+13%+48%
Medical Devices
The closest names by size in the same industry